Bridion

Bridion

sugammadex

Manufacturer:

MSD

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Sugammadex
Indications/Uses
Reversal of neuromuscular blockade induced by rocuronium or vecuronium. Routine reversal of rocuronium-induced blockade in childn & adolescents.
Dosage/Direction for Use
Single IV bolus inj Adult Routine reversal 4 mg/kg if recovery reached at least 1-2 post-tetanic counts (PTC) or 2 mg/kg if spontaneous recovery occurred up to reappearance of T2 following rocuronium- or vecuronium-induced blockade. Immediate reversal of rocuronium-induced blockade 16 mg/kg administered 3 min after bolus dose of rocuronium Br 1.2 mg/kg. Recurrence of neuromuscular blockade post-op Repeat dose of 4 mg/kg. Childn & adolescent 2-17 yr Routine reversal 2 mg/kg at reappearance of T2.
Contraindications
Special Precautions
Hypersensitivity including anaphylactic reactions. Additional activated partial thromboplastin time & prothrombin time prolongation; light anesth &/or opioid. Marked bradycardia. Increased risk of recurrence of neuromuscular blockade. Waiting times for re-administration w/ neuromuscular blocking agents. Patients receiving rocuronium or vecuronium in ICU setting; on controlled Na diet. Not to be used for reversal of block induced by nonsteroidal neuromuscular blockers (eg, succinylcholine or benzylisoquinolinium compd) or steroidal neuromuscular blockers other than rocuronium or vecuronium; reversal of pancuronium induced blockade. Monitor for signs of recurrence of neuromuscular blockade approx 15 min after parenteral administration of another medicinal product occurring w/in 7.5 hr. Delayed recovery time in CV disease, elderly or edematous state. Adequate ventilation following extubation. Monitor resp function during recovery; coagulation parameters in patients w/ known coagulopathies & those using anticoagulants; for hemodynamic changes during & after reversal. Concomitant use w/ medicinal products which potentiate neuromuscular blockade in post-op period; hormonal contraceptives; toremifene & fusidic acid. Not recommended in severe renal impairment; patients requiring dialysis (CrCl <30 mL/min). Severe hepatic impairment. Pregnancy & lactation. Immediate reversal in childn & adolescents. Not recommended in term newborn infants (<30 days) & infants (30 days-2 yr). Elderly.
Adverse Reactions
Anesth airway complication, anaesth & procedural complication, procedural hypotension; cough.
Drug Interactions
Displacement of vecuronium or rocuronium w/ toremifene. Delayed recovery time w/ fusidic acid IV. Reduced effects of hormonal contraceptives eg, progestogen.
MIMS Class
Antidotes & Detoxifying Agents
ATC Classification
V03AB35 - sugammadex ; Belongs to the class of antidotes. Used to reverse neuromuscular blockade caused by rocuronium or vecuronium.
Presentation/Packing
Form
Bridion soln for inj 100 mg/mL
Packing/Price
2 mL x 10 × 1's;5 mL x 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in